40th week of 2015 patent applcation highlights part 11 |
Patent application number | Title | Published |
20150272983 | METHOD OF INDUCING OSTEOGENSIS AND PROMOTING OSSEOINTEGRATION AROUND AN IMPLANT - The invention relates to a method of inducing osteogenesis in a subject comprising administrating a chitosan material to the a subject in need of osteogenesis, wherein the chitosan material having a chitosan with a degree of deacetylation at the range of 70%˜90%, and the chitosan is 0.15% by weight of the chitosan material. The method of the present invention can induce bone-forming and promote osseointegration around an implant. | 2015-10-01 |
20150272984 | AGENTS FOR THE PREVENTION AND/OR TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE - The present invention relates to the use of agents (including heparin derivatives) for the prevention and/or treatment of CNS damage. | 2015-10-01 |
20150272985 | COMPOSITION AND METHOD TO ALLEVIATE JOINT PAIN USING LOW MOLECULAR WEIGHT HYALURONIC ACID AND ASTAXANTHIN - A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of joint pain. The composition includes pro-inflammatory low molecular weight microbial fermented sodium hyaluronate fragments and glucosamine in an oral dosage form. | 2015-10-01 |
20150272986 | COMPOSITION FOR ALLEVIATING CONDITIONS ASSOCIATED WITH VAGINAL DRYNESS - A composition for alleviating conditions associated with vaginal dryness comprising a thickener, a non-ionic, water-soluble poly(ethylene oxide) polymer having molecular weight of at least 100,000 Da, and at least 95 wt % water. | 2015-10-01 |
20150272987 | SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION - Provided herein are pre-formulations forming a biocompatible hydrogel polymer comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the biocompatible hydrogel polymer covers a wound in a mammal and adheres to the surrounding skin tissue. In other embodiments, the hydrogel polymer is delivered into a joint space to treat joint disease or navicular disease. | 2015-10-01 |
20150272988 | INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES - A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters. | 2015-10-01 |
20150272989 | Physical Optimization Beverage - The present invention provides novel methods of making a non-corrosive base solution for use as an alkalinity increasing agent and/or antioxidant. The compositions and methods described herein are useful for optimizing health and performance; preventing illness; decreasing recovery times from exertion, illness, and injury; increasing energy levels; improving exercise performance; improving hydration; preventing muscle damage after exercise; and increasing stamina during exercise. The present invention further provides novel compositions and methods which can be used to provide relief from disorders related to or complicated by acidosis or excessive free radical or other reactive oxygen species production. | 2015-10-01 |
20150272990 | PROCESS FOR THE PREPARATION OF A NON-CORROSIVE BASE SOLUTION AND METHODS OF USING SAME - The present invention provides novel methods of making a non-corrosive base solution for use as an alkalinity increasing agent and/or antioxidant. The present invention further provides novel compositions and methods which can be used to provide relief from acidosis, acidemia, and disorders related to or complicated by acidosis or excessive free radical or other reactive oxygen species production in mammalian subjects. | 2015-10-01 |
20150272991 | USE OF CHROMIUM HISTIDINATE FOR TREATMENT OF CARDIOMETABOLIC DISORDERS - Provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising chromium and histidine, chromium histidinate complexes, or combinations thereof, to the individual. | 2015-10-01 |
20150272992 | Treatment of Tumors with Activated Mesenchymal Stem Cells - A method of treating a tumor in an animal by administering to the animal mesenchymal stem cells that have been contacted with a stimulating, or activating agent, such as TNF-a, that stimulates the mesenchymal stem cells to express increased amounts of at least one agent, such as TRAIL and/or DKK-3, that inhibits, prevents, or destroys the growth of tumors. The stimulated, or activated mesenchymal stem cells may be administered in combination with at least one chemotherapeutic agent, such as doxorubicin. | 2015-10-01 |
20150272993 | Combined Organ and Hematopoietic Cells For Transplantation Tolerance of Grafts - Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance. | 2015-10-01 |
20150272994 | MESENCHYMAL STROMAL CELLS AND USES RELATED THERETO - The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies. | 2015-10-01 |
20150272995 | In Vivo and Ex Vivo Expansion of Hematopoietic Stem Cells With a Targeted Combination of Clinically Tested, FDA Approved Drugs - The present invention provides a therapeutic approach to maintain and expand HSCs in vivo using currently available medications that target GSK-3 and mTOR. The present invention also provides a system and method for the ex vivo culturing of HSCs, where an mTOR inhibitor is combined with a GSK-3 inhibitor within the culturing conditions. | 2015-10-01 |
20150272996 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT - Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation. | 2015-10-01 |
20150272997 | Mesenchymal Stem Cells and Uses Therefor - Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting wound healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount. | 2015-10-01 |
20150272998 | COMPOSITION COMPRISING CELL AND BIOCOMPATIBLE POLYMER - It is an object of the present invention to provide a cell-containing composition capable of suppressing the outflow of the cells after transplantation and improving the survival rate of the cells. The present invention provides a composition which comprises any of bone marrow stromal cell-derived neural precursor cells, bone marrow stromal cell-derived Schwann cells, or bone marrow stromal cell-derived skeletal muscle cells; and a biocompatible polymer. | 2015-10-01 |
20150272999 | RETROGRADE CORONARY VEIN DELIVERY OF STEM CELLS - The present invention relates to the delivery of stem cells to heart tissue by retrograde coronary vein infusion. The invention also provides methods useful for treating subjects with heart disease. | 2015-10-01 |
20150273000 | PROBIOTIC COMPOSITION FOR ORAL HEALTH - The present invention provides a composition comprising an effective amount of | 2015-10-01 |
20150273001 | Cesium Eliminator - A dietary supplement comprising powdered ingredients: zeolite powder: 70%-5%, dehydrated seaweed: 5%-25%, seawater extract: 5%-10% | 2015-10-01 |
20150273002 | METHODS AND COMPOSITIONS FOR TREATMENT OF HEMATOLOGIC CANCERS - The present invention relates to oncolytic Picornaviruses and methods and compositions for treating subjects having hematologic cancers. These include methods and compositions for treatment of myeloma, using disclosed Picornavirus such as Coxsackievirus, in methods of direct or indirect administration to subjects and ex vivo purging of malignant cells within auto grafts prior to transplantation. | 2015-10-01 |
20150273003 | STABLE FORMULATIONS - The present invention relates to a formulation comprising extracts of | 2015-10-01 |
20150273004 | Plant Parts and Extracts Having Anticoccidial Activity - Natural plant parts and extracts of plants selected from the group consisting of | 2015-10-01 |
20150273005 | Pharmaceutical Composition for Increasing Content and Availability of Cyclic Adenosine Monophosphate in a Body and Preparation Thereof - The present invention discloses a pharmaceutical composition to rapidly increase a content and an availability of a cyclic adenosine monophosphate (cAMP) in a body, including: ginsenosides Rg1, Rb1 and Re, a | 2015-10-01 |
20150273006 | METHODS AND COMPOSITIONS FOR ENHANCING HAIR QUALITY USING BLACKBERRY EXTRACT - Compositions and methods for inducing hair growth and improving hair quality utilizing extracts of blackberry in an amount effective to induce hair growth when applied topically to an area of the skin on which hair growth is desired. | 2015-10-01 |
20150273007 | BLOOD PRESSURE REDUCTION WITH DIETARY SUPPLEMENTS - A daily dose of 6,000 mg of taurine, 1,000 mg of vitamin C, 150 mg of grape seed extract, 100 mg of vitamin B6, 2 mg of biotin, 2,000 IU of vitamin D3, and 87 mg of magnesium is shown to reduce blood pressure in hypertensive individuals by more than 10 mm Hg. | 2015-10-01 |
20150273008 | HEAVY METALS DEFENSE - A dietary supplement comprising powdered ingredients: a) dehydrated seaweed: 40-60 wt. %, b) seawater extract: 20-40 wt. %, c) grape seed powder: 10-20 wt. %, d) | 2015-10-01 |
20150273009 | NEW FORMULATIONS COMPRISING PLANT EXTRACTS - The present invention is related to a formulation comprising | 2015-10-01 |
20150273010 | HIGH-THROUGHPUT ASSAYS FOR HIV-1 ENVELOPE MATURATION AND NOVEL PEPTIDE INHIBITORS AGAINST HIV-1 - The invention provides peptide inhibitors against human immunodeficiency virus (HIV), including HIV-1, and compositions, formulations, and pharmaceutical compositions comprising same, and methods of making and using them. The invention provides methods for treating, ameliorating, slowing the progress of, reversing, or preventing a retroviral infection, an HIV infection, or an HIV-1 infection, or AIDS. In alternative embodiments, the invention provides compositions, including pharmaceutical compositions and formulations, comprising peptides or polypeptide having a sequence as set forth in SEQ ID NO:1 and/or SEQ ID NO:2, and peptidomimetics and bioisosteres thereof. In alternative embodiments, the invention provides cell-based platforms, multiplexed systems or platforms, or cell-based methods, for monitoring the activity of an HIV-1 protease (PR) enzyme, or for screening for a substrate of the HIV-1 protease (PR) enzyme. | 2015-10-01 |
20150273011 | TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING - A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0001 to about 5 mg, alternatively about 0.0001 to about 3 mg, alternatively about 0.0005 to about 1.2 mg, alternatively about 0.0005 to about 1.0 mg, alternatively about 0.00075 to about 1.0 mg, alternatively about 0.001 mg to about 1.0 mg, alternatively about 0.001 mg to about 0.8 mg, alternatively about 0.001 mg to about 0.7 mg, alternatively about 0.001 mg to about 0.6 mg. Methods of administering a topical analgesic containing a neo-tryptophan-containing neurotensin analog are also described. The topical analgesic can be administered in a patch, gel, lotion, spray, or mist. | 2015-10-01 |
20150273012 | USE OF DEGARELIX IN THE TREATMENT OF ENDOMETRIOSIS AND RELATED DISEASES - The use of degarelix in the treatment of endometriosis, in particular in the treatment of endometriotic ovarian cysts and recurrent endometriotic lesions following surgery and in the treatment of endometriosis and/or endometriotic ovarian cysts in patients who plan to undergo assisted reproduction, is described, wherein this treatment is performed before the patients are subjected to assisted reproduction; degarelix is administered for this purpose as a single dose of 80-120 mg, preferably 80 mg, subcutaneously. | 2015-10-01 |
20150273013 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS - The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer), a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder) by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases. | 2015-10-01 |
20150273014 | USE OF PEPTIDES FOR PROMOTING WOUND HEALING - The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications. | 2015-10-01 |
20150273015 | TREATMENTS OF HEPATITIS C VIRUS INFECTION - The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis C virus infection. | 2015-10-01 |
20150273016 | GENE THERAPY FOR GLYCOGEN STORAGE DISEASES - The present invention relates to a transcription factor EB (TFEB) protein, ortholog, recombinant or synthetic or bio technological functional derivative thereof, allelic variant thereof and fragments thereof; a chimeric molecule comprising the TFEB protein, ortholog, recombinant or synthetic or biotechnological functional derivative thereof, allelic variant thereof and fragments thereof; a polynucleotide coding for said protein or ortholog, recombinant or synthetic or biotechnological functional derivative thereof, allelic variant thereof and fragments thereof; a vector comprising said polynucleotide; a host cell genetically engineered expressing said polypeptide or a pharmaceutical composition for use in the treatment or/and prevention of a glycogen storage disease. Preferably of Pompe or Danon disease. | 2015-10-01 |
20150273017 | Novel Method for Treating Cardiac Infarction Using HMGB1 Fragment - A fragment peptide having a proper length composed of a part of an HMGB1 protein was synthesized and the peptide was confirmed to exhibit therapeutic effects on myocardial infarction. | 2015-10-01 |
20150273018 | SYNTHETIC PEPTIDE FOR INHIBITING EXPRESSION OF TYPE 2 TNF RECEPTOR AND USE THEREOF - This invention provides an artificially synthesized peptide having an activity to inhibit the expression of type 2 TNF receptor (TNF-R2), and a TNF-R2 expression-inhibiting composition including the peptide as an active ingredient. Also provided is a method for inhibiting the expression of TNF-R2 in cells capable of expressing TNF-R2, by using the peptide. The expression of TNF-R2 in the cells is inhibited, by supplying the cells capable of expressing TNF-R2 with a synthetic peptide essentially including of an amino acid sequence constituting a signal peptide in an amyloid precursor protein (APP) or an amino acid sequence formed by substituting, deleting and/or adding one or several amino acid residues in/from/to the amino acid sequence of the signal peptide. | 2015-10-01 |
20150273019 | METHOD OF TREATING WOUNDS - A novel composition and method of treating a wound is provided. The method comprises administering a therapeutically effective amount of periostin and/or CCN2 proteins to the wound. | 2015-10-01 |
20150273020 | Hormone Normalization Therapy and Uses Therefor - The present invention discloses methods of prevention of oocyte and fetal aneuploidy, birth defects, miscarriages and infertility in women. The three therapies, disclosed herein, the hormone normalization therapy, the aromatase inhibitor-hormone normalization therapy, and the low responder hormone normalization therapy with estrogenic supplementation focus on restoring young hormonal levels in women in order to prevent female infertility and miscarriages, guide follicular and oocyte maturation, follicular responsiveness, and promote correct chromosomal segregation in oocytes and early embryos. | 2015-10-01 |
20150273021 | COMPOSITIONS AND METHODS FOR SUSTAINED DELIVERY OF GLUCAGON-LIKE PEPTIDE (GLP-1) RECEPTOR AGONIST THERAPEUTICS - The present invention is directed to silk-based drug delivery compositions or compositions for sustained delivery of therapeutic agent(s), such as glucagon-like peptide (GLP-1) receptor agonists, as well as methods of making and using the same. | 2015-10-01 |
20150273022 | STABILIZED ULTRA-RAPID-ACTING INSULIN FORMULATIONS - Compositions and methods for enhancing the stability of rapid acting injectable insulin formulations have been developed for subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid (“EDTA”), a dissolution/stabilization agent such as citric acid, a magnesium salt, a zinc compound and, optionally, additional excipients. New presentations include rapid acting concentrated insulin formulations and a way to enhance the absorption of commercially available rapid acting analog formulations while maintaining insulin stability. | 2015-10-01 |
20150273023 | Use of PEGylated IGF-I Variants For The Treatment Of Neuromuscular Disorders - The present invention relates to a pharmaceutical composition containing a PEGylated IGF-I variant derived from the wild-type human IGF-I amino acid sequence where one or two of the lysine amino acids at positions 27, 65, and 68 are altered to be a polar amino acid other than lysine and where the PEG is attached to at least one lysine residue. The invention also relates to methods for the treatment, prevention and/or delay of progression of neuromuscular disorders, in particular amyotrophic lateral sclerosis (ALS) by administering a therapeutically effective amount of the pharmaceutical composition of the invention. | 2015-10-01 |
20150273024 | BIOMARKERS FOR H-NOX DELIVERY OF OXYGEN - The invention provides methods to monitor tumor oxygenation by H-NOX proteins. H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. For example, the invention provides methods to monitor brain tumor oxygenation by H-NOX proteins for enhanced treatment of brain cancers. | 2015-10-01 |
20150273025 | APYRASE TREATMENTS - Provided herein is technology relating to compositions comprising apyrase and particularly, but not exclusively, to compositions comprising apyrase, methods of treating with apyrase, and uses of apyrase related to treating a subject, e.g., a subject suffering from a microbial infection, a subject who has a wound or burn and is in need of an antimicrobial treatment, and/or a subject in need of treatment for heterotopic ossification. | 2015-10-01 |
20150273026 | Clinical Applications for Recombinant Human MxA Protein - Full length MxA constructs and truncated MxA constructs produce human MxA protein in | 2015-10-01 |
20150273027 | LIQUID PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDE - The invention relates to a liquid, aqueous pharmaceutical composition comprising a Factor VIIa polypeptide, a buffering agent suitable for keeping pH in the range of from about 5.5 to about 8.5; and an active site stabilizing agent, which is selected from the group of: (S)-2-{2-[5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2′-dihydroxy-5′-sulfamoyl-biphenyl-3-yl]acetylamino}-succinic acid or a pharmaceutically acceptable salt thereof; (R)-2-{2-[5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2′-dihydroxy-5′-sulfamoyl-biphenyl-3-yl]acetylamino}-succinic acid or a pharmaceutically acceptable salt thereof; and a mixture of the (S)- and (R)-forms or pharmaceutically acceptable salts thereof. The invention further relates to said composition for treatment of a Factor VII-responsive bleeding disorder; methods for preparing the liquid composition and for stabilizing Factor VIIa in a liquid aqueous composition; an air-tight container containing the liquid, aqueous pharmaceutical composition and optionally an inert gas; and a method of treating a Factor VII-responsive bleeding disorder in a patent. | 2015-10-01 |
20150273028 | USE OF COLLAGENASE TO TREAT GLAUCOMA - Provided is a method of treatment for reducing fibrosis involving administering purified collagenase into an anterior chamber of an eye of a human patient. | 2015-10-01 |
20150273029 | RETROVIRAL VECTOR WITH MINI-PROMOTER CASSETTE - This disclosure provides a retroviral replicating vector for gene delivery comprising a therapeutic cassette containing at least one mini-promoter linked to a gene to be expressed. | 2015-10-01 |
20150273030 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYMPTOMS OF PRION DISEASES - A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of a prion disease, or the likelihood of an individual to develop a prion disease is disclosed. | 2015-10-01 |
20150273031 | METHODS AND COMPOSITIONS FOR VACCINATING AGAINST STAPHYLOCOCCUS AUREUS - The invention features a method of vaccinating a mammal against | 2015-10-01 |
20150273032 | NOVEL REGULATORY T CELL EPITOPE AND HEPATITIS C VIRUS HOMOLOG - A pharmaceutical composition used to suppress immunity in an animal, wherein the pharmaceutical composition comprises an isolated T-cell epitope peptide containing an amino acid sequence of PLLLLL | 2015-10-01 |
20150273033 | COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER - The present disclosure arises at least in part from the seminal recognition that a combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, or a medically beneficial response by a tumor. | 2015-10-01 |
20150273034 | GLOBO H AND RELATED ANTI-CANCER VACCINES WITH NOVEL GLYCOLIPID ADJUVANTS - An immunogenic composition containing a glycan conjugate including a carrier protein, and a glycan including Globo H, an immunogenic fragment thereof, or stage-specific embryonic antigen-4 (SSEA-4), wherein the glycan is conjugated with the carrier protein through a linker. | 2015-10-01 |
20150273035 | VACCINATION AGAINST JAPANESE ENCEPHALITIS, MEASLES, MUMPS AND RUBELLA - The invention relates to a method of vaccinating against Japanese encephalitis (JE), measles, mumps and rubella which comprises co-administering to a patient in need, MMR vaccine and a live attenuated or inactivated cell culture derived JE vaccine. | 2015-10-01 |
20150273036 | NON-CROSS-LINKED ACELLULAR PERTUSSIS ANTIGENS FOR USE IN COMBINATION VACCINES - The present invention relates to stable compositions comprising acellular pertussis antigens that have not been cross-linked with a cross-linking agent such as formaldehyde or glutaraldehyde and their use as acellular pertussis components in combination vaccines. Processes for preparing these antigens and compositions are also disclosed. | 2015-10-01 |
20150273037 | Immunogenic composition against Campylobacter jejuni - The inventive subject matter relates to an immunogenic composition against | 2015-10-01 |
20150273038 | COMPOSITIONS AND METHODS FOR ENTEROHEMORRHAGIC ESCHERICHIA COLI (EHEC)VACCINATION - Certain embodiments are directed to compositions comprising EHEC-specific antigens. In certain aspects EHEC O157:H7-specific antigen(s) are used as components of immunogenic compositions and vaccines. | 2015-10-01 |
20150273039 | Compositions Comprising Soluble HLA/M. Tuberculosis-Specific Ligand Complexes and Methods of Production and Use Thereof - Compositions that include at least one isolated, class I HLA trimolecular complex that includes a peptide ligand unique to | 2015-10-01 |
20150273040 | COMPOSITIONS AND METHODS RELATED TO ANTIBODIES THAT NEUTRALIZE COAGULASE ACTIVITY DURING STAPHYLOCOCCUS AUREUS DISEASE - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 2015-10-01 |
20150273041 | STAPHYLOCOCCUS AUREUS SDRE CNAB DOMAIN AND ITS USE FOR VACCINATION | 2015-10-01 |
20150273042 | PILUS PROTEINS AND COMPOSITIONS - The invention provides methods of forming pili in vitro and proteins suitable for use in these methods. The invention also provides pili produced by these methods and compositions comprising these pili for the treatment and prevention of bacterial disease, in particular of conditions caused by | 2015-10-01 |
20150273043 | PRODUCTION OF RECOMBINANT VACCINE IN E.COLI BY ENZYMATIC CONJUGATION - Prokaryotic cells proficient to produce glycoconjugates in vivo are provided herein, as well as methods for generating these cell and methods of using these cells to produce glycoconjugates. The compositions of the mentioned glycoconjugates as well as their different uses are also included. | 2015-10-01 |
20150273044 | METHODS OF INDUCING AN IMMUNE RESPONSE WITH COMPOSITIONS COMPRISING A NEISSERIA MENINGITIDIS 741 PROTEIN - Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH | 2015-10-01 |
20150273045 | Immunological Compositions Containing Attenuated Histophilus somni - This disclosure provides attenuated | 2015-10-01 |
20150273046 | PROPHYLAXIS AND TREATMENT OF PRDC - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs. | 2015-10-01 |
20150273047 | VACCINE - The present invention relates to the field of vaccines for protecting against polio, and in particular to combination vaccines for protecting against polio, diphtheria, tetanus, and pertussis diseases. Specifically, vaccines comprising reduced dose inactivated poliovirus (IPV) is provided, which can maintain an adequate or improved level of protection against polio. | 2015-10-01 |
20150273048 | UNIVERSAL INFLUENZA VACCINE BASED ON HETEROLOGOUS MULTIPLE M2E PROTEINS - Disclosed are universal influenza A vaccines capable of providing broader crossprotection. The vaccine contains a fusion protein comprising tandem repeats of heterologous M2e epitope sequences that have been molecularly and genetically designed to provide broad cross-protection. The fusion protein may be incorporated into virus-like particles (VLPs) or a replicating live attenuated influenza virus vaccine, and administered alone or in combination with other influenza vaccines. | 2015-10-01 |
20150273049 | GENETICALLY ENGINEERED SWINE INFLUENZA VIRUS AND USES THEREOF - The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations. | 2015-10-01 |
20150273050 | Formulations for Non-invasive Delivery of Active Proteins to an Animal or Human - This invention relates to formulations which contain at least one active peptide intended to be used for prevention or treatment of a condition in an animal or human. Said active peptide has been expressed in a system that improves the conservation of those properties essential to the prophylactic or therapeutic effect of said peptide before and after delivery to an animal or human and until the peptide delivers its activity at the effector site within said animal or human. The invention is particularly relevant to formulations of oral or mucosal vaccines or biopharmaceuticals. The active peptide of the formulation is recombinantly expressed in cells or whole animals. In a preferred embodiment of this invention the active polypeptide of the formulation has been recombinantly expressed in insect cells or whole insect larvae. | 2015-10-01 |
20150273051 | Improved Human Herpesvirus Immunotherapy - An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens. | 2015-10-01 |
20150273052 | Modification of Allergens for Immunotherapy - The present invention relates to pharmaceutical compositions for immunotherapy, for example for immunotherapy of peanut allergy. Further, the present invention relates to methods for the preparation of the present pharmaceutical compositions for immunotherapy, and their use in immunotherapy. | 2015-10-01 |
20150273053 | Methods to enhance T-cell mediated immune response - The present invention provides methods for restoring or enhancing T cell mediated immune response in individuals of middle and advanced age. | 2015-10-01 |
20150273054 | Modulation of CCR10 Signals for Treatment of Skin and Intestinal Inflammatory Diseases and Infection - The invention provides compositions and methods for targeting CCR10 and/or the CCR10/ligand axis to modulate the immune response in a subject. | 2015-10-01 |
20150273055 | METHODS AND COMPOSITIONS FOR EXPANDING HEMATOPOIETIC STEM AND PROGENITOR CELLS - Provided herein are methods for increasing the number of hematopoietic stem and progenitor cells (HSPCs) in vivo or in vitro. The methods can include the steps of selecting a subject in need of an increased number of HSPCs and administering to the subject an effective amount of an inhibitor of VEGF to increase the number of HSPCs in the subject. Optionally, the methods include the steps of contacting a population of HSPCs and supporting cells with an inhibitor of VEGF, and contacting the population of HSPCs and supporting cells with a parathyroid hormone (PTH) receptor agonist. Also provided is a method for increasing the number of hematopoietic stem and progenitor cells (HSPCs) in a subject including the steps of administering to the subject an inhibitor of VEGF, and administering to the subject a parathyroid hormone (PTH) receptor agonist. The method is optionally used in a subject or for a with decreased osteogenesis, including, for example, when the subject has a bone fracture or has osteoporosis. Compositions and kits for increasing the number of HSPCs comprising (i) one or more doses of an inhibitor of VEGF; and (ii) one or more doses of a PTH receptor agonist are also provided. | 2015-10-01 |
20150273056 | ENHANCEMENT OF THE IMMUNE RESPONSE - The technology described herein relates to compositions and methods for enhancing the immune response and/or reducing T cell tolerance in a subject. In some embodiments, the technology described herein relates to administering inhibitors of two or more of CEACAM1, PD1, and/or LAP to, e.g., synergistically reduce T cell tolerance. | 2015-10-01 |
20150273057 | Combination - A novel combination comprising a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and/or the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and an EGFR inhibitor suitably cetuximab (Erbitux) or erlotinib; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf and/or EGFR is beneficial, eg. cancer. | 2015-10-01 |
20150273058 | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever - The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved. | 2015-10-01 |
20150273059 | EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS - The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab. | 2015-10-01 |
20150273060 | DELIVERY COMPOSITIONS AND METHODS - This disclosure describes composition and methods for delivering a substance to a subject. Generally, the compositions include a liposome that includes a lysolipid and a cargo composition at least partially encapsulated by the liposome; and a reversibly heatable component coupled to the liposome. Generally, the method includes administering such a composition to a subject and causing localized release of the cargo composition by heating the reversibly heatable component of a localized portion of the composition. | 2015-10-01 |
20150273061 | DEGRADABLE SILICA NANOSHELLS FOR ULTRASONIC IMAGING/THERAPY - Disclosed are methods using degradable silica nanoshells for local intra-operative ultrasound marking; tumor detection via systemic injection; and nanoshell enhanced ultrasonic ablation of tumors. | 2015-10-01 |
20150273062 | MAGNESIUM HYDROXIDE CARBONATE AS CARRIER MATERIAL IN ACTIVE INGREDIENT-CONTAINING PREPARATIONS - The present invention relates to solid formulations which contain at least one porous carrier and one or more functional substances in a stable mixture, and to the use thereof. | 2015-10-01 |
20150273063 | MARKERS FOR PHARMACEUTICALS - Provided are methods for labeling a pharmaceutical product to indicate the origin, and/or intended recipient, and/or a predetermined characteristic (e.g. geographic location) of an intended recipient of the pharmaceutical product. The methods include incorporating certain pharmaceutically inactive marker substances into the pharmaceutical product at manufacture. | 2015-10-01 |
20150273064 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-10-01 |
20150273065 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-10-01 |
20150273066 | CONVENIENTLY IMPLANTABLE SUSTAINED RELEASE DRUG COMPOSITIONS - This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states. | 2015-10-01 |
20150273067 | SOLID CARRIERS FOR IMPROVED DELIVERY OF ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS - The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents. | 2015-10-01 |
20150273068 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS - The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid. | 2015-10-01 |
20150273069 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY - The present invention relates to oral pharmaceutical compositions comprising a GLP-1 peptide and a fatty acid acylated amino acid and use thereof. | 2015-10-01 |
20150273070 | MODIFIED RELEASE OF 4-METHYL-3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]-N-[5-(4-METHYL-1H-IMIDA- ZOL-1-YL)-3-(TRIFLOUOROMETHYL)PHENYL] BENZAMIDE SOLUBILIZED USING ORGANIC ACIDS - Soluble pharmaceutical compositions of nilotinib or a pharmaceutically acceptable salt thereof were invented using one or more organic acids that function as a solubilizing agent, increasing the bioavailability of nilotinib and supressing the food effect associated with certain compositions of nilotinib. The pharmaceutical compositions are in the form of solid oral dosage forms, including capsules and tablets. | 2015-10-01 |
20150273071 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery - Degradable polymers were synthesized that self-assemble with nucleic acids, proteins, hydrophobic drugs, and other small molecules to form particles that are effective for delivery into a cell, tissue and/or organism either in vitro or in vivo. The presently disclosed polymers demonstrate differential cell-type specificity, an ability to promote endosomal escape to protect the cargos from degradation and enhance delivery to the cytoplasm, and/or bioreducibility, which enables triggered intracellular drug release to be tuned to promote optimal delivery to the target cell type. The presently disclosed materials may be used to treat a wide variety of conditions or diseases, such as cancer, cardiovascular diseases, infectious diseases, and ophthalmic diseases. | 2015-10-01 |
20150273072 | THERMO-SENSITIVE, MUCOADHESIVE OR DERMOADHESIVE, AND PENETRATION-ENHANCING FORMULATIONS FOR TOPICAL DELIVERY OF THERAPEUTICS - The present invention provides thermo-sensitive, mucoadhesive biopolymer formulations that enhance the penetration of therapeutics across the skin or mucosal surfaces. In a preferred embodiment, the biopolymer formulation comprises co-polymer of poloxamer 188 and propylene glycol, laurocapram and, optionally, one or more therapeutic agents. Also provided are uses of the biopolymer formulations for topical therapy of cancer including cervical cancer. | 2015-10-01 |
20150273073 | TRIAZINE CATIONIC POLYMERS AND METHODS OF USE THEREOF - The present invention provides compounds of Formula I or Formula II: | 2015-10-01 |
20150273074 | Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same - The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers find for conjugating to molecules such as targeting, diagnostic and therapeutic agents. | 2015-10-01 |
20150273075 | THERAPEUTIC USES OF MODIFIED FGF-21 POLYPEPTIDES COMPRISING NON-NATURALLY OCCURRING AMINO ACIDS - Modified FGF-21 polypeptides and uses thereof are provided. | 2015-10-01 |
20150273076 | SP1 POLYPEPTIDES, MODIFIED SP1 POLYPEPTIDES AND USES THEREOF - SP1 and modified SP1 variant polypeptides capable of forming reversible molecular associations with substances, compositions-of-matter comprising same, and uses thereof are provided. | 2015-10-01 |
20150273077 | PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES - Conjugates of an antibody that binds to HER2 with PBD dimers. | 2015-10-01 |
20150273078 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES - Conjugates of an antibody that binds to PSMA with PBD dimers. | 2015-10-01 |
20150273079 | IMMUNOMODULATOR PARTICLES AND METHODS OF TREATING - A method of stimulating an immune response in a subject including administering a micrometer-sized particle coupled with an antigen to the subject, wherein increasing the aspect ratio of the micrometer-sized particle increases the immune response. A method of stimulating an immune response in a subject including administering to the subject a plurality of particles, wherein each particle is coupled with an immuno stimulating agent and a protein. A vaccine particle composition including a plurality of particles configured to release a first protein at a first rate and a second protein at a second rate and configured to provide priming and boosting capability in a single dose. | 2015-10-01 |
20150273080 | REDUCTION STIMULUS-RESPONSIVE GENE DELIVERY SYSTEM AND PREPARATION AND APPLICATION THEREOF - The present invention discloses a gene delivery system containing a reduction-sensitive shielding system having a targeting function, a preparation method and an application in the field of gene therapy thereof. The gene delivery system is composed of a reduction-sensitive shielding system having a targeting function, cationic polymer material and plasmid DNA; the cationic polymer material and the plasmid DNA complexed to form complex particles, the reduction-sensitive shielding system having a targeting function is shielded on the complex surface by means of electrostatic interaction, so as to reduce the toxicity of the delivery system and successfully transfer the loaded genetic material into cells, thereby achieving expression of genetic material and completing the transfection process, and moreover, improving the targeting and the efficiency of gene transfection. | 2015-10-01 |
20150273081 | Reversibly Masked Polymers - The present invention is directed to reversibly inactivated membrane active polymers useful for cellular delivery of compounds. Described are polyconjugate systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery conjugates. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation. | 2015-10-01 |
20150273082 | OPTIMISED CODING SEQUENCE AND PROMOTER - An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocyte biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment. | 2015-10-01 |